Development and Qualification of Visible Particle Load Analysis Methods for Injectable Drug Product Primary Packaging Components

References

1. 1.↵
   1. Wang H.

   Regulatory Perspective on Inspection of Injectable Products for Visible Particulates. Parenteral Drug Association Aseptic Processing of Biopharmaceuticals: Fill-Finish Technology and Patient-Friendly Devices, Virtual, October 12–14, 2020.
2. 2.↵
   U.S. Pharmacopeial Convention, General Chapter <1> Injections and Implanted Drug Product (Parenterals)—Product Quality Tests. In USP 42–NF 37, USP, Rockville, MD, 2019; pp 6339–6343.
3. 3.↵
   Council of Europe, Parenteral Preparations, Monograph 0520. In European Pharmacopoeia (Ph. Eur.), 9th Edition, Council of Europe, Strasbourg, France, 2016; pp 871–873.
4. 4.↵
   Ministry of Health Labour and Welfare of Japan, General Tests, Processes and Apparatus—6.06: Foreign Insoluble Matter Test for Injection. In The Japanese Pharmacopoeia, 17th Edition (English Version), MHLW: Tokyo, 2016; p 151.
5. 5.↵
   1. Langille S. E.

   Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   U.S. Pharmacopeial Convention, General Chapter <787> Subvisible Particulate Matter in Therapeutic Protein Injections. In USP 40–NF 35, USP, Rockville, MD, 2017; pp 663–664.
7. 7.↵
   U.S. Pharmacopeial Convention, General Chapter <788> Particulate Matter in Injections. In USP 40–NF 35, USP, Rockville, MD, 2017; pp 665–668.
8. 8.↵
   U.S. Pharmacopeial Convention, General Chapter <1787> Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections. In USP 40–NF 35, USP, Rockville, MD, 2017; pp 2149–2162.
9. 9.↵
   U.S. Pharmacopeial Convention, General Chapter <1788> Particulate Matter in Injections and Ophthalmic Solutions. In USP 40–NF 35, USP, Rockville, MD, 2017; pp 2163–2172.
10. 10.↵
    U.S. Pharmacopeial Convention, General Chapter <790> Visible Particulates in Injections. In USP 42–NF 37, USP, Rockville, MD, 2019; p 6947.
11. 11.↵
    U.S. Pharmacopeial Convention, General Chapter <1790> Visual Inspection of Injections. In USP 41–NF 36, USP, Rockville, MD, 2018; pp 8066–8083.
12. 12.↵
    1. Mathonet S.,
    2. Mahler H.-C.,
    3. Esswein S. T.,
    4. Mazaheri M.,
    5. Cash P. W.,
    6. Wuchner K.,
    7. Kallmeyer G.,
    8. Das T. K.,
    9. Finkler C.,
    10. Lennard A.

    A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 392–408.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Rech J.,
    2. Fradkin A.,
    3. Krueger A.,
    4. Kraft C.,
    5. Paskiet D.

    Evaluation of Particle Techniques for the Characterization of Subvisible Particles from Elastomeric Closure Components. J. Pharm. Sci. 2020, 109 (5), 1725–1735.

    OpenUrl
14. 14.↵
    International Organization for Standardization, ISO 8871-3:2003 Elastomeric Parts for Parenterals and for Devices for Pharmaceutical Use—Part 3: Determination of Released-Particle Count. ISO: Geneva, Switzerland, 2003.
15. 15.↵
    1. McPherson E.,
    2. Bingham C.,
    3. Carter D.,
    4. Toomey W.,
    5. Scofield M.,
    6. Pulvirenti R.

    Quantification and Identification of Visible and Subvisible Particulates from Elastomeric Components Contributing to the Total Particle Count of Pharmaceutical Products. Microsc. Microanal. 2017, 23 (S1), 1218–1219.

    OpenUrl
16. 16.↵
    U.S. Pharmacopeial Convention, General Chapter <660> Containers—Glass. In USP 42–NF 37, USP, Rockville, MD, 2019; pp 6806–6811.
17. 17.↵
    U.S. Pharmacopeial Convention, General Chapter <661> Plastic Packaging Systems and Their Materials of Construction. In USP 42–NF 37, USP, Rockville, MD, 2019; pp 6812–6818.
18. 18.↵
    1. Johns J.,
    2. Golfetto P.,
    3. Bush T.,
    4. Fantozzi G.,
    5. Shabushnig J.,
    6. Perry A.,
    7. Degrazio F.,
    8. Streich D.,
    9. Miller J.,
    10. Soukiassian H.,
    11. Stanton A.,
    12. Watson R.

    Achieving “Zero” Defects for Visible Particles in Injectables. PDA J. Pharm. Sci. Technol. 2018, 72 (6), 640–650.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    Parenteral Drug Association Inc. PDA Technical Report No. 85: Enhanced Test Methods for Visible Particle Detection and Enumeration on Elastomeric Closures and Glass Containers; Bethesda, MD, 2021.
20. 20.↵
    1. Langille S. E.

    Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach. PDA J. Pharm. Sci. Technol. 2020, 74 (3), 359–366.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Makwana S.,
    2. Basu B.,
    3. Makasana Y.,
    4. Dharamsi A.

    Prefilled Syringes: An Innovation in Parenteral Packaging. Int. J. Pharm. Invest. 2011, 1 (4), 200–206.

    OpenUrl
22. 22.↵
    Brandessence Market Research. Global Safety & Prefilled Syringe Market Size By Product Type (Retractable Safety Syringe, Non-Retractable Safety Syringe) By Application (Insulin, Others) By End User (Hospitals, Others) Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 – 2027. https://brandessenceresearch.com/medical-device/safety-prefilled-syringes-market (accessed August 2, 2021).